INT93207

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 4.32
Pain Relevance 2.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (Cyp4a3)
Anatomy Link Frequency
liver 1
Cyp4a3 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
fluoxetine 26 99.92 Very High Very High Very High
anticonvulsant 4 99.88 Very High Very High Very High
Paracetamol 15 98.48 Very High Very High Very High
sSRI 16 96.12 Very High Very High Very High
lidocaine 12 93.80 High High
carbamazepine 10 92.80 High High
headache 7 86.04 High High
anesthesia 4 81.56 Quite High
antidepressant 30 79.84 Quite High
depression 95 75.48 Quite High
Disease Link Frequency Relevance Heat
Fatty Liver 1 100.00 Very High Very High Very High
Bacterial Infection 9 99.72 Very High Very High Very High
Arrhythmia Under Development 2 98.22 Very High Very High Very High
Toxicity 2 97.96 Very High Very High Very High
Arrhythmias 2 Under Development 1 97.74 Very High Very High Very High
Injury 66 97.72 Very High Very High Very High
Cv Unclassified Under Development 7 97.12 Very High Very High Very High
Manic Depressive Disorder 95 93.60 High High
Overdose 4 92.84 High High
Renal Disease 1 91.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Rapid reduction of liver steatosis in omega3-depleted rats injected with a novel lipid emulsion.
Negative_regulation (reduction) of omega3-depleted in liver associated with fatty liver
1) Confidence 0.36 Published 2008 Journal Horm. Metab. Res. Section Title Doc Link 18726832 Disease Relevance 0.18 Pain Relevance 0.08
The place of origin seemed to be of minor importance for CYP3A4 or P-gp inhibition.
Negative_regulation (inhibition) of CYP3A4
2) Confidence 0.34 Published 2010 Journal Planta Med. Section Abstract Doc Link 19790032 Disease Relevance 0 Pain Relevance 0.08
All clones showed potent inhibition of CYP3A4 and P-gp activities, with IC (50) values ranging from 1.7 to 3.1 microg/mL and from 16.7 to 51.7 microg/mL, respectively, being below that reported for other herbs and some known classic drug inhibitors, such as St.
Negative_regulation (inhibition) of CYP3A4
3) Confidence 0.34 Published 2010 Journal Planta Med. Section Abstract Doc Link 19790032 Disease Relevance 0 Pain Relevance 0.08
Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea.
Negative_regulation (inhibition) of CYP3A4
4) Confidence 0.34 Published 2010 Journal Planta Med. Section Title Doc Link 19790032 Disease Relevance 0 Pain Relevance 0.06
The CYP3A4 was significantly reduced after endotoxic shock.
Negative_regulation (reduced) of CYP3A4 associated with bacterial infection
5) Confidence 0.33 Published 2002 Journal Shock Section Abstract Doc Link 11900338 Disease Relevance 0.33 Pain Relevance 0.52
Stiripentol (STP); (200 mg/kg), an anticonvulsant drug inhibitor of CYP1A2 and CYP3A4 in vivo in humans was tested against APAP-induced toxicity in rat in comparison with N-acetylcysteine (NAC; 100 mg/kg).
Negative_regulation (inhibitor) of CYP3A4 associated with toxicity, paracetamol and anticonvulsant
6) Confidence 0.02 Published 2001 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 11162779 Disease Relevance 0.66 Pain Relevance 0.89
Subsequently their cardiac toxicity, e.g. ventricular fibrillation and torsades de pointes was discovered when they were given systemically, in high doses and in combination with CYP3A4 inhibitors.
Negative_regulation (inhibitors) of CYP3A4 associated with cv unclassified under development, arrhythmia under development and arrhythmias 2 under development
7) Confidence 0.02 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792619 Disease Relevance 1.57 Pain Relevance 0.07
On the other hand, the coadministration of ketoconazole, a potent inhibitor of the CYP3A4 enzyme system, decreases quetiapine clearance.


Negative_regulation (inhibitor) of CYP3A4
8) Confidence 0.01 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671777 Disease Relevance 0.89 Pain Relevance 0.10
Thus, fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor; fluoxetine and paroxetine are potent CYP2D6 inhibitors; sertraline is a moderate CYP2D6 inhibitor; and citalopram has little effect on the major cytochrome-P450 isoforms (Hemeryck and Belpaire 2002).
Negative_regulation (inhibitor) of CYP3A4 associated with fluoxetine
9) Confidence 0.01 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515899 Disease Relevance 0.52 Pain Relevance 0.62
Studies have shown that memantine produces minimal inhibition of CYP450 enzymes CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4, indicating that no pharmacokinetic interactions with drugs metabolized by these enzymes are expected.
Negative_regulation (inhibition) of CYP3A4
10) Confidence 0.01 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0.18 Pain Relevance 0.03
Concomitant drugs that either induce or inhibit CYP3A4 may alter serum concentrations of zonisamide.
Negative_regulation (inhibit) of CYP3A4
11) Confidence 0.00 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox